These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 2053304)
1. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis]. Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304 [TBL] [Abstract][Full Text] [Related]
2. [Soluble interleukin-6 receptors in the serum in multiple myeloma]. Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823 [TBL] [Abstract][Full Text] [Related]
3. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease]. Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349 [TBL] [Abstract][Full Text] [Related]
4. [Clinical importance of the paraprotein index in multiple myeloma]. Papajík T; Bacovský J; Zadrazil J; Budíková M; Faltýnek L; Scudla V Vnitr Lek; 1994 Aug; 40(8):502-5. PubMed ID: 7941436 [TBL] [Abstract][Full Text] [Related]
5. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma]. Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma. Scudla V; Vavrdová V; Budíková M; Indrák K Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347 [TBL] [Abstract][Full Text] [Related]
7. [Serum beta-2-microglobulin in multiple myeloma. Practical value]. Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091 [TBL] [Abstract][Full Text] [Related]
8. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease]. Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566 [TBL] [Abstract][Full Text] [Related]
9. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Perosa F; Minoia C; Favoino E; Prete M; Dammacco F Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035 [TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases]. Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681 [TBL] [Abstract][Full Text] [Related]
11. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869 [TBL] [Abstract][Full Text] [Related]
13. Serum beta 2 microglobulin in multiple myeloma and related plasma cell dyscrasias. Pasquini E; Tiraferri E; Fattori PP; Fabbri I; Gobbi M Haematologica; 1987; 72(1):17-21. PubMed ID: 3108090 [No Abstract] [Full Text] [Related]
14. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease]. Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146 [TBL] [Abstract][Full Text] [Related]
15. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients]. Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938 [TBL] [Abstract][Full Text] [Related]
16. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma]. Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177 [TBL] [Abstract][Full Text] [Related]
17. [Importance of determining the propidium-iodide index of plasmacytes in multiple myeloma. I. Relation to selected laboratory indicators of the disease]. Scudla V; Ordeltová M; Spidlová A; Bacovský J; Kurasová J; Vránová M Vnitr Lek; 1999 Jun; 45(6):331-5. PubMed ID: 11045167 [TBL] [Abstract][Full Text] [Related]
18. [Serum ferritin and beta-2-microglobulin in multiple myeloma]. Linkesch W; Ludwig H Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172 [TBL] [Abstract][Full Text] [Related]
19. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY; Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800 [TBL] [Abstract][Full Text] [Related]
20. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma. Linkesch W; Ludwig H Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]